Oleh
Dandy Firmansyah
Disetujuitanggal :
Dipresentasikantanggal :
i
LEMBAR PENGESAHAN
Oleh:
Dandy Firmansyah
ii
DAFTAR ISI
HALAMAN JUDUL...............................................................................................i
HALAMAN PENGESAHAN................................................................................ii
DAFTAR ISI..........................................................................................................iii
DAFTAR GAMBAR.............................................................................................iv
DAFTAR TABEL...................................................................................................v
BAB I. PENDAHULUAN.......................................................................................1
A. Angioedema
B. Tes Alergi
C. Alergi Obat
DAFTAR PUSTAKA.............................................................................................37
iii
DAFTAR GAMBAR
Gambar 4 Foto pasien saat perawatan hari ke- 10 (3 hari setelah angioedema
terjadi)....................................................................................................10
Gambar 5 Foto pasien saat perawatan hari ke-15( 8 hari setelah angioedema
terjadi).....................................................................................................14
iv
DAFTAR TABEL
v
DAFTAR PUSTAKA
1. Stokes SC, Tankersley MS. HIV: Practical implications for the practicing allergist–
2. Rancinan C, Morlat P, Chêne G, Guez S, Baquey A, Beylot J, et al. IgE serum level: A
prognostic marker for AIDS in HIV-infected adults? J Allergy Clin Immunol 1998;102:329-
30.
allergic diseases and total serum IgE levels among HIV-infected children. Eur Ann Allergy
vi
5 Phillips E, Mallal S (2007) Drug hypersensitivity in HIV. CurrOpin Allergy
Clin Immunol 7: 324-330.
16. Naisbitt DJ, Vilar FJ, Stalford AC, Wilkins EG, Pirmohamed M, et al.
(2000) Plasma cysteine deficiency and decreased reduction of
nitrososulfamethoxazole with HIV infection. AIDS Res Hum Retroviruses
16: 1929-1938.
17. Walmsley SL, Winn LM, Harrison ML, Uetrecht JP, Wells PG, et al. (1997)
Oxidative stress and thio depletion in plasma and peripheral blood
lymphocytes from HIV-infected patients: toxicological and pathological
implications. AIDS 11: 1689-1697.
69. Lee BL, Safrin S. Interactions and toxicities of drugs used in patients with AIDS. Clin
70. Koopmans PP, vanderVen AJ, Vree TB, et al. Pathogenesis of hypersensitivity
1995;9:217–222. IV.
1993; 57:183-233.
8. Lin RY. Chronic diffuse dermatitis and hyper-IgE in HIV infection. Acta Derm Venerol.
1988;68(6):486-91.
vii
15. Carr A, Cooper DA, Penny R. Allergic manifestations of human immunodeficiency
16. Wright DN, Nelson RP, Ledford DK, et al. Serum IgE and human immunodeficiency
17. Lucey DR, Zajac RA, Melcher GP, et al. Serum IgE levels in 622 persons with human
Immunol. 1995;95:995-1003.
19. Bacot BK, Paul ME, Navarro M, Abramson SL, Kline MW, Hanson IC, et al. Objective
20. Koutsonikolis A, Nelson RP, Fernandez-Caldas E, Brigino EN, Seleznick M, Good RA, et
al. Serum total and specific IgE levels in children infected with human
72. Carr A, Swanson R, Penny R, et al. Clinical and laboratory markers of hypersensitivity
viii
73. Bayard P, Berger T, Jacobson M. Drug hypersensitivity reactions and human
IV.
298. Rieder MJ, Shear NH, Kanee A, et al. Prominence of slow acetylator phenotype
1991;49:13–17. IIa.
499. Carr A, Penny R, Cooper DA. Efficacy and safety of rechallenge with low-dose
500. Carr A, Gross AS, Hoskins JM, et al. Acetylation phenotype and cutaneous
501. Lehmann DF, Liu A, Newman N, et al. The association of opportunistic infections
1999;39:533–537. III.
502. Lee BL, Wong D, Benowitz NL, et al. Altered patterns of drug metabolism in patients
535. III.
ix
503. Walmsley SL, Khorasheh S, Singer J, et al. A randomized trial of N-acetylcysteine for
504. Rieder MJ, Krause R, Bird IA, et al. Toxicity of sulfonamide-reactive metabolites in
505. Battegay M, Opravil M, Wuthrich B, et al. Rash with amoxicillin clavulanate therapy
72. Carr A, Swanson R, Penny R, et al. Clinical and laboratory markers of hypersensitivity
499. Carr A, Penny R, Cooper DA. Efficacy and safety of rechallenge with low-dose
507. Pertel P, Hirschtick R. Adverse reactions to dapsone in persons injected with human
x
508. O’Neil CE, Reed MA, Lopez M, et al. Evaluation of immune parameters in HIV
509. Daftarian MP, Filion LG, Cameron W, et al. Immune response to sulfamethoxazole
in patients with AIDS. Clin Diagn Lab Immunol. 1995;2:199 –204. III.
with AIDS who were previously intolerant to TMP-SMZ. Clin Infect Dis.
76. Nguyen M, Weiss PJ, Wallace MR. Two-day oral desensitization to trimethoprim-
358. III.
xi
79. Caumes E, Guermonprez G, Lecomte C, et al. Efficacy and safety of desensitization
III.
81. Ryan C, Madalon M, Wortham DW, et al. Sulfa hypersensitivity in patients with HIV
1998;97:23–27. III.
1036. III.
49. Ib.
virus type-1 infection who were previously intolerant to T/S. Ann Allergy Asthma
xii
85. Moreno JN, Poblete RB, Maggio C, et al. Rapid oral desensitization for sulfonamides
505. Battegay M, Opravil M, Wuthrich B, et al. Rash with amoxicillin clavulanate therapy
512. Holtzman DM, Kaku DA, So YT. New-onset seizures associated with human
513. Jacobson MA, Besch CL, Child C, et al. Toxicity of clindamycin as prophylaxis for
xiii
514. Kennedy C, Goetz M, Mathisen G. Ciprofloxacin-induced anaphylactoid reactions in
1990;153:563–564. III.
164. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T,
Auquier A, Bastuji-Garin S, Correia O, Locati F, et al. Medication
use and the risk of Stevens-Johnson syndrome or toxic epidermal
necrolysis. N Engl J Med. 1995;333:1600–1607. [PubMed]
xiv
necrolysis and Stevens-Johnson
syndrome. Pharmacogenetics. 1995;5:25525–25528. [PubMed]
306. [PubMed]
Jick 1982
Kovacs 1984
Wharton 1986
xv
Wharton JM, Coleman DL, Wofsy CB, Luce JM, Blumenfeld
37-44.
Medina 1990
Hughes 1993
xvi
Clumeck N, Masur H, Lancaster D, Chan C, Lavelle J, Rosenstock
Jaffe 1983
Jaffe HS, Abrams DI, Ammann AJ, Lewis BJ, Golden JA. Complications
1109-1111.
Gordin 1984
495-499.
Small 1985
Small CB, Harris CA, Friedland GH, Klein RS. The treatment of
xvii
Pneumocystis carinii pneumonia in the acquired immunode_ciency
Fischl 1988
1988;259:1185-9.
Hardy 1992
Schneider 1992
xviii
TL, van der Graaf Y, Frissen JP, van der Ende IM, Kolsters AF, Borleffs
of medicine 1992;327:1836-41.
Grimwade 2003
www.who.int/entity/hiv/pub/guidelines/ctxguidelines.pdf
6. World Health Organization. [August 15, 2013] Consolidated guidelines on the use of
http://www.who.int/hiv/pub/guidelines/arv2013/.
xix
19. Grimwake K, Sturm A, Nunn J, Mbatha D, Zungu D, Gilks C. Effectiveness
Benson 2004
Phair 1990
Klatt 1994
xx
Los Angeles, Calif, 1982-1993. Archives of pathology & laboratory
medicine 1994;118:884-90.
UNAIDS 2004
Gilks 1990
Gilks CF, Ojoo SA, Ojoo JC, Brindle RJ, Paul J, Batchelor BI, Kimari
Abouya 1992
disease 1992;145:617-20.
xxi
Grant 1997
1357-64.
Wannamethee 1998
1998;27:289-95.
Joshi 2002
McNaghten 1999
xxii
McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW.
Kaplan 2000
diseases 2000;30:S5-14.
Wiktor 1999
xxiii
a randomised controlled trial. Lancet 1999;353:1469-75.
Chintu 2004
1865-71.
Mwaungulu 2004
Grimwade 2005
xxiv
with tuberculosis in rural South Africa. AIDS 2005;19:163-8.
WHO 2006
2. Castells M, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, et al. Hypersensitivity
1 Turvey SE1, Cronin B, Arnold AD, Dioun AF, 2004. Antibiotic desensitization for
Apr;92(4):426-32.
xxv